Regeneus stem cell therapy reaches Melbourne

Regeneus (ASX:RGS) has announced that its stem cell therapy HiQCell is now available in Melbourne for the first time.

The company has established a new cell-processing laboratory at Linley Clinic Private Hospital in collaboration with sports and exercise physician Dr Philip Bloom at Bounce Health Group.

HiQCell is an autologous point-of-care therapy for musculoskeletal conditions including osteoarthritis. It is designed to reduce inflammation and repair damaged tissue.

The therapy is derived from a patient’s adipose (fat) tissue, as extracted by a treating medico. Regeneus staff then use the tissue to prepare a cell therapy in-clinic.

The therapy has to date been used in over 800 joints from more than 350 people in New South Wales and Queensland, but this launch marks a debut in Victoria.

Regeneus is also developing Cryoshot, an allogeneic cell therapy for joint conditions in animals, and has a human product based on the same technology in preclinical trials.

The company recently concluded a $10.5 million IPO, the first Australian biotech float since 2011.

Regeneus (ASX:RGS) shares grew 4% on Wednesday to $0.255 after the debut was announced.